WESPAC Advisors SoCal’s Acadia Pharmaceuticals ACAD Stock Holding History

WESPAC Advisors SoCal’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$5K	–	87
2019 Q1	$5K	Hold	200	–	–	﹤0.01%	280
2018 Q4	$3K	Hold	200	–	–	﹤0.01%	299
2018 Q3	$4K	Buy	+200	New	+$3.15K	﹤0.01%	269
2018 Q2	–	Sell	-200	Closed	-$4K	–	92
2018 Q1	$4K	Hold	200	–	–	﹤0.01%	228
2017 Q4	$6K	Sell	200 -1,000	-83%	-$32K	﹤0.01%	203
2017 Q3	$45K	Hold	1,200	–	–	0.03%	129
2017 Q2	$33K	Hold	1,200	–	–	0.02%	130
2017 Q1	$41.3K	Buy	+1,200	New	+$42.4K	0.03%	123

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WESPAC Advisors SoCal's ACAD Position: Q2 2019 in Review

WESPAC Advisors SoCal sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 200 shares — an estimated $5K sold.

WESPAC Advisors SoCal first reported a position in ACAD in Q1 2017 and held it in 8 quarters. The position peaked at $45K in Q3 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

WESPAC Advisors SoCal reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
WESPAC Advisors SoCal sold 200 Acadia Pharmaceuticals shares in Q2 2019, an estimated $5K.
WESPAC Advisors SoCal first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 8 quarters.
WESPAC Advisors SoCal's Acadia Pharmaceuticals position peaked at $45K in Q3 2017.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2019, filed 30 Jul 2019.